Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation for patients with small cell lung cancer and advances that include prophylactic cranial radiotherapy, thoracic radiotherapy, and the use of PET-CT.
Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
Robert W. Carlson, MD, Chief Executive Officer of the National Comprehensive Cancer Network, and Lee N. Newcomer, MD, MHA, of UnitedHealthCare, discuss the value of NCCN Guidelines in determining coverage decisions, the future of affordable care, bundled payments, and the clear value approach.
